

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 June 2009 (25.06.2009)

PCT

(10) International Publication Number
WO 2009/078798 A1

(51) International Patent Classification:

C07D 473/18 (2006.01) *A61P 31/12* (2006.01)
A61K 31/5377 (2006.01) *A61P 31/18* (2006.01)
A61P 11/00 (2006.01) *A61P 35/00* (2006.01)
A61P 11/06 (2006.01) *A61P 37/02* (2006.01)
A61P 17/00 (2006.01) *A61P 37/08* (2006.01)

Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **SCHULZ, Håkan** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2008/051465

(22) International Filing Date:

16 December 2008 (16.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/014,164 17 December 2007 (17.12.2007) US

(71) Applicants (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **DAINIPPON SUMITOMO PHARMA CO., LTD** [JP/JP]; 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka-fu, Osaka, 5418524 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MCINALLY, Thomas** [GB/GB]; AstraZeneca R & D Charnwood,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ [3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL] (3- MORPHOLIN-4-YL) PROPYL) AMINO] METHYL } PHENYL) ACETATE AND THEIR USE IN THERAPY

(57) Abstract: The present invention concerns hydrochloric acid, hydrobromic acid and maleic acid salts of methyl (3-{ [3-(6-amino-2- butoxy-8-oxo-7, 8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl} phenyl) acetate, compositions comprising them and their use in therapy.

WO 2009/078798 A1